Works matching IS 15747891 AND DT 2023 AND VI 17 AND IP 11


Results: 17
    1
    2
    3
    4
    5
    6
    7
    8

    Lasting response by vertical inhibition with cetuximab and trametinib in KRAS‐mutated colorectal cancer patient‐derived xenografts.

    Published in:
    Molecular Oncology, 2023, v. 17, n. 11, p. 2396, doi. 10.1002/1878-0261.13510
    By:
    • Reissig, Timm M.;
    • Ladigan‐Badura, Swetlana;
    • Steinberg, Anja;
    • Maghnouj, Abdelouahid;
    • Li, Ting;
    • Verdoodt, Berlinda;
    • Liffers, Sven T.;
    • Pohl, Michael;
    • Wolters, Heiner;
    • Teschendorf, Christian;
    • Viebahn, Richard;
    • Admard, Jakob;
    • Casadei, Nicolas;
    • Tannapfel, Andrea;
    • Schmiegel, Wolff;
    • Hahn, Stephan A.;
    • Vangala, Deepak B.
    Publication type:
    Article
    9

    Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α.

    Published in:
    Molecular Oncology, 2023, v. 17, n. 11, p. 2235, doi. 10.1002/1878-0261.13508
    By:
    • Biziotis, Olga‐Demetra;
    • Tsakiridis, Evangelia Evelyn;
    • Ali, Amr;
    • Ahmadi, Elham;
    • Wu, Jianhan;
    • Wang, Simon;
    • Mekhaeil, Bassem;
    • Singh, Kanwaldeep;
    • Menjolian, Gabe;
    • Farrell, Thomas;
    • Abdulkarim, Bassam;
    • Sur, Ranjan K.;
    • Mesci, Aruz;
    • Ellis, Peter;
    • Berg, Tobias;
    • Bramson, Jonathan L;
    • Muti, Paola;
    • Steinberg, Gregory R;
    • Tsakiridis, Theodoros
    Publication type:
    Article
    10
    11

    Issue Information.

    Published in:
    Molecular Oncology, 2023, v. 17, n. 11, p. 2213, doi. 10.1002/1878-0261.13241
    Publication type:
    Article
    12
    13
    14

    Histone‐lysine N‐methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc‐driven liver cancer.

    Published in:
    Molecular Oncology, 2023, v. 17, n. 11, p. 2275, doi. 10.1002/1878-0261.13417
    By:
    • Thng, Dexter Kai Hao;
    • Hooi, Lissa;
    • Toh, Clarissa Chin Min;
    • Lim, Jhin Jieh;
    • Rajagopalan, Deepa;
    • Syariff, Imran Qamar Charles;
    • Tan, Zher Min;
    • Rashid, Masturah Bte Mohd Abdul;
    • Zhou, Lei;
    • Kow, Alfred Wei Chieh;
    • Bonney, Glenn Kunnath;
    • Goh, Brian Kim Poh;
    • Kam, Juinn Huar;
    • Jha, Sudhakar;
    • Dan, Yock Young;
    • Chow, Pierce Kah Hoe;
    • Toh, Tan Boon;
    • Chow, Edward Kai‐Hua
    Publication type:
    Article
    15

    MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)‐dependent oncogenic driver in vitro and in humanised HGF knock‐in mice.

    Published in:
    Molecular Oncology, 2023, v. 17, n. 11, p. 2257, doi. 10.1002/1878-0261.13397
    By:
    • Fernandes, Marie;
    • Hoggard, Brynna;
    • Jamme, Philippe;
    • Paget, Sonia;
    • Truong, Marie‐José;
    • Grégoire, Valérie;
    • Vinchent, Audrey;
    • Descarpentries, Clotilde;
    • Morabito, Angela;
    • Stanislovas, Justas;
    • Farage, Enoir;
    • Meneboo, Jean‐Pascal;
    • Sebda, Shéhérazade;
    • Bouchekioua‐Bouzaghou, Katia;
    • Nollet, Marie;
    • Humez, Sarah;
    • Perera, Timothy;
    • Fromme, Paul;
    • Grumolato, Luca;
    • Figeac, Martin
    Publication type:
    Article
    16
    17